Last reviewed · How we verify

almotriptan or pseudoephedrine

Clinvest · FDA-approved active Small molecule

almotriptan or pseudoephedrine is a Triptan + sympathomimetic decongestant combination Small molecule drug developed by Clinvest. It is currently FDA-approved for Acute migraine with or without aura, with associated nasal congestion.

This is a combination product containing almotriptan (a selective 5-HT1B/1D receptor agonist for migraine) and pseudoephedrine (a sympathomimetic nasal decongestant).

This is a combination product containing almotriptan (a selective 5-HT1B/1D receptor agonist for migraine) and pseudoephedrine (a sympathomimetic nasal decongestant). Used for Acute migraine with or without aura, with associated nasal congestion.

At a glance

Generic namealmotriptan or pseudoephedrine
SponsorClinvest
Drug classTriptan + sympathomimetic decongestant combination
Target5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine)
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Almotriptan works by binding to serotonin 5-HT1B and 5-HT1D receptors on cranial blood vessels and nerve terminals, causing vasoconstriction and reducing neurogenic inflammation associated with migraine. Pseudoephedrine acts as an alpha-adrenergic agonist to reduce nasal congestion. The combination targets both migraine symptoms and associated sinus congestion.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about almotriptan or pseudoephedrine

What is almotriptan or pseudoephedrine?

almotriptan or pseudoephedrine is a Triptan + sympathomimetic decongestant combination drug developed by Clinvest, indicated for Acute migraine with or without aura, with associated nasal congestion.

How does almotriptan or pseudoephedrine work?

This is a combination product containing almotriptan (a selective 5-HT1B/1D receptor agonist for migraine) and pseudoephedrine (a sympathomimetic nasal decongestant).

What is almotriptan or pseudoephedrine used for?

almotriptan or pseudoephedrine is indicated for Acute migraine with or without aura, with associated nasal congestion.

Who makes almotriptan or pseudoephedrine?

almotriptan or pseudoephedrine is developed and marketed by Clinvest (see full Clinvest pipeline at /company/clinvest).

What drug class is almotriptan or pseudoephedrine in?

almotriptan or pseudoephedrine belongs to the Triptan + sympathomimetic decongestant combination class. See all Triptan + sympathomimetic decongestant combination drugs at /class/triptan-sympathomimetic-decongestant-combination.

What development phase is almotriptan or pseudoephedrine in?

almotriptan or pseudoephedrine is FDA-approved (marketed).

What are the side effects of almotriptan or pseudoephedrine?

Common side effects of almotriptan or pseudoephedrine include Chest pain or tightness, Dizziness, Somnolence, Paresthesia, Tremor, Palpitations.

What does almotriptan or pseudoephedrine target?

almotriptan or pseudoephedrine targets 5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine) and is a Triptan + sympathomimetic decongestant combination.

Related